Severe Acute Respiratory Syndrome Corona Virus (SARS-CoV-2) is the causative agent of
COVID-19 pandemic, which has resulted in global fatalities since late December 2019 …

Objectives This study investigated the association between nirmatrelvir plus ritonavir (NMV-
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …

The ongoing COVID-19 pandemic continues to present surges in infections demonstrating
the persistent threat posed by COVID-19. Amidst efforts to develop effective treatments for …

Within a multistate clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated
from April 2022–June 2023 among nonhospitalized patients with SARS-CoV-2 with risk …

Molnupiravir, the prodrug for β-D-N4-hydroxycytidine (NHC), is marketed by Merck as
Lagevrio™ against mild–moderate COVID-19, under FDA emergency use authorization. It is …

Summary Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19 …

Introduction Molnupiravir is an orally available prodrug of N-hydroxycytidine that received
special approval for emergency treatment of coronavirus disease 2019 (COVID-19) in Japan …

Introduction Oral antiviral medications are important tools for preventing severe COVID-19
outcomes. However, their uptake remains low for reasons that are not entirely understood …

Objective: The objective of this study was to evaluate the therapeutic efficacy of
ursodeoxycholic acid (UDCA) and mesenchymal stem cells (MSCs) in patients with severe …

Objectives Although guidelines recommend antiviral therapy for outpatients with COVID-19
who are at high risk of progressing to severe conditions, such as older adults, many patients …